Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

4367

Accredited to ISO 17043:2010

EMQN C.I.C.

Issue No: 013 **Issue date:** 26 February 2024

Unit 4
Enterprise House
Pencroft Way
Manchester Science Park
Manchester
M15 6SE

Contact: Dr Simon Patton
Tel: +44(0) 161 757 1591
E-Mail: office@emqn.org
Website: www.emqn.org

Proficiency Tests provided from the above address only

DETAIL OF ACCREDITATION

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
Human DNA (from blood and/or lymphoblastoid cell lines)	**Genomic and Inherited Disorders EQA Schemes** – Genotyping, results interpretation and reporting **Note** [1]Gene panel scheme (or includes optional gene panel) Autosomal Dominant Polycystic Kidney disease (ADPKD)[1] Beckwith-Wiedemann and Silver-Russel syndromes (BWS / SRS)[1] Cardiac genetics Arrhythmia (Cardio ARR)[1] Cardiac genetics, Hypertrophic Cardio Myopathy (Cardiac HCM)[1] Charcot-Marie-Tooth disease (CMT) and Hereditary Neuropathy with liability for Pressure Palsies (HNPP)[1] Congenital Adrenal Hyperplasia (CAH)[1] Duchenne / Becker Muscular Dystrophy (DMD / BMD)[1] Familial hypercholesterolemia (FH)[1]	See scheme catalogue available from www.emqn.org

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
Human DNA (from blood and/or lymphoblastoid cell lines) (cont'd)	**Genomic and Inherited Disorders EQA Schemes** - Genotyping result interpretation, and reporting (cont'd) **Note** [1]Gene panel scheme (or includes optional gene panel) Fragile X syndrome (FRAX) Friedreich Ataxia (FRDA) Hereditary Breast and Ovarian Cancer (Panel testing)[1] Breast and Ovarian BRCA1/BRCA2 targeted testing only)[1] Hereditary Hearing Loss (DFNB1)[1] Hereditary Hemochromatosis (HFE) Huntington Disease (HD) Lynch syndrome (HNPCC)[1] Mitochondrial DNA disorders (mtDNA) Monogenic Diabetes (MODY)[1] Multiple Endocrine Neoplasia (Type 2) (MEN2) Myotonic Dystrophy (DM) Osteogenesis Imperfecta (OI) Phenylketonuria (PKU) Polyposis syndromes; Familial Adenomatous Polyposis (FAP) and MUTYH-associated polyposis (MAP) 1[1] Porphyrias (POR)[1]	See scheme catalogue available from www.emqn.org

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
Human DNA (from blood and/or lymphoblastoid cell lines) (cont'd)	**Genomic and Inherited Disorders EQA Schemes** - Genotyping result interpretation, and reporting (cont'd) **Note** [1]Gene panel scheme (or includes optional gene panel) Prader-Willi and Angelman syndromes (PWAS) Rare Neurological disease genes (RND) Retinoblastoma (RB) *RYR1* related Myopathies and Malignant Hyperthermia Severe Combined Immunodeficiency (SCID)[1] Short stature homeobox genes testing (SHOX) Spinal Muscular Atrophy (SMA) Spinocerebellar Ataxias (SCA)[1] Stickler syndrome (STICKLER)[1] Systemic Autoinflammatory Diseases (SAID)[1] Von Hippel Lindau syndrome (VHL) Wilson Disease (WIL) Y-Chromosome Microdeletion testing (AZF)	See scheme catalogue available from www.emqn.org

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Molecular Pathology schemes - Genotyping and results interpretation and reporting	See scheme catalogue available from www.emqn.org
Human DNA (from blood and/or lymphoblastoid cell lines)	Breast, Ovarian and Pancreatic cancers (PARPi, DNA Germline)	
Formalin fixed, paraffin embedded (FFPE) materials (from solid tissues and /or cell line reference materials)	Breast cancer (AKT, Tissue)	
	Colorectal Cancer (COLORECTAL, Tissue)	
	Lung cancer - common biomarkers (LUNG (NSCLC), Tissue – COMMON)	
	Lung cancer - new and emerging biomarkers (LUNG (NSCLC), Tissue – EMERGING)	
	Melanoma (MELANOMA, Tissue)	
	Microsatellite Instability testing (MSI, Tissue)	
	Ovarian and Prostate cancers (PARPi, Tissue)	
Artificial plasma	Lung cancer (LUNG (NSCLC), Plasma)	
	Molecular Pathology schemes - Genotyping only	
Formalin fixed, paraffin embedded (FFPE) materials (from solid tissues and /or cell line reference materials)	Oncogene panel testing (ONCOGENE PANEL, Tissue)	

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used
	Pre and Postnatal EQA schemes - Genotyping, results interpretation and reporting	See scheme catalogue available from www.emqn.org
Human DNA (from blood and/or lymphoblastoid cell lines)	Postnatal constitutional CNV (array CGH/NGS Postnatal CNV)	
Artificial plasma	Non-invasive prenatal testing – sex determination (NIPT SEXING)	
	Non-invasive prenatal testing – aneuploidies including the sex chromosomes (NIPT ANEUPLOIDY)	
	Pharmacogenetic Testing EQA schemes - Genotyping, results interpretation and reporting	See scheme catalogue available from www.emqn.org
Human DNA (from blood and/or lymphoblastoid cell lines)	Pharmacogenetics panel scheme (PHARMACO, Panel)	
	Technology focussed EQA schemes - Data quality assessment +/- genotyping	See scheme catalogue available from www.emqn.org
Human DNA (from blood and/or lymphoblastoid cell lines)	DNA Sequencing (Sanger Sequencing) (SANGER)	
	DNA Sequencing - NGS germline SNVs and indels (NGS vGERMLINE)	
END		